NEW YORK (GenomeWeb) – Startup Bluestar Genomics, a spinout of the Stephen Quake lab at Stanford University, has uncovered a link between an epigenomic signal in cell-free DNA (cfDNA) and pancreatic cancer in patients.

Based on its findings, Bluestar is developing a non-invasive liquid biopsy assay that tracks epigenetic modifications linked to gene regulation and pancreatic cancer pathogenesis in circulating cfDNA in patient blood samples.

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.